AbbVie bags major European label expansion for VENCLYXTO in chronic lymphocytic leukemia

The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,

Pfizer's LORBRENA delivers landmark seven-year survival results in advanced lung cancer trial

The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer

AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial

The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis

Sun's cancer drug shines delivering 50% response rate with long-lasting tumor control

These data support clinically meaningful efficacy within this patient population. We observed a high rate of complete responses in patients with laCSCC

Lilly posts strong early clinical results for one-shot gene-editing cholesterol therapy

A one-shot gene-editing cholesterol therapy could soon be a reality

AstraZeneca breast cancer drug wins key EU backing after cutting progression risk by 56%

The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial

Merck doses first patient in Phase 3 trial of novel antibody-drug conjugate for metastatic colorectal cancer

The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments

Eli lilly’s retatrutide delivers up to 30% weight loss in phase 3 trial

Clears major obesity endpoints at 80 weeks

Pfizer advances next-gen pneumococcal vaccine after strong Phase 2 infant data

Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials

SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer

The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients

Bayer’s NUBEQA combo shows 71% drop in risk of progression or death in prostate cancer trial

Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm

ParexelAI launched to accelerate clinical development and improve trial efficiency

The platform combines internally developed technologies, strategic partnerships, and external AI capabilities

Merck reports breakthrough Phase 3 win for sac-TMT in endometrial cancer

Imfinzi-based regimens deliver major survival gains in muscle-invasive bladder cancer

The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents

Edwards Lifesciences highlights 10-year data reinforcing durability of RESILIA tissue

Suven Life Sciences reaches 76% milestone in Phase 3 masupirdine trial for Alzheimer’s agitation

The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies

Breakthrough wearable heart failure therapy enables earlier hospital discharge: UK trial

Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care

6th Drug Safety Symposium 2026 to convene over 100 pharmacovigilance leaders

Mumbai event on June 24–25 will spotlight real-world impact of pharmacovigilance beyond AI adoption

Moderna’s mRNA flu vaccine outperforms standard shot in Phase 3 trial

NEJM study shows strong protection across strains

GRIN Therapeutics launches Phase 3 beeline study in Europe for radiprodil in GRIN-NDD

This is an exciting and meaningful milestone for GRIN Therapeutics